OCUL
Ocular Therapeutix Inc
NASDAQ: OCUL · HEALTHCARE · BIOTECHNOLOGY
$9.21
-1.18% today
Updated 2026-04-29
Market cap
$2.00B
P/E ratio
—
P/S ratio
38.59x
EPS (TTM)
$-1.42
Dividend yield
—
52W range
$6 – $16
Volume
4.9M
Ocular Therapeutix Inc (OCUL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-526.00%
ROE
-54.80%
ROA
-26.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $10000.00 | $-14.09M | 30.00% | -136,710.00% | -140,930.00% |
| 2013 | — | $-13.32M | — | — | — |
| 2014 | $772000.00 | $-28.65M | 88.21% | -3,509.59% | -3,710.88% |
| 2015 | $1.75M | $-39.75M | 81.77% | -2,182.69% | -2,271.31% |
| 2016 | $1.89M | $-44.70M | 76.52% | -2,296.03% | -2,369.00% |
| 2017 | $1.92M | $-63.39M | 76.24% | -3,220.12% | -3,296.20% |
| 2018 | $1.99M | $-57.69M | 76.63% | -2,970.75% | -2,899.10% |
| 2019 | $4.23M | $-86.37M | 45.00% | -2,029.86% | -2,043.34% |
| 2020 | $17.40M | $-155.64M | 88.03% | -361.13% | -894.31% |
| 2021 | $43.52M | $-6.55M | 89.88% | -179.30% | -15.06% |
| 2022 | $51.49M | $-71.04M | 91.18% | -152.74% | -137.95% |
| 2023 | $58.44M | $-80.74M | 90.96% | -140.96% | -138.14% |
| 2024 | $63.72M | $-193.51M | 91.17% | -269.57% | -303.67% |
| 2025 | $51.82M | $-265.94M | 87.31% | -521.04% | -513.17% |